

# Therapies for COVID-19

---

## Medical policy no. 19.50.20

### Background:

Distribution and use of COVID-19 therapies for the treatment of mild to moderate COVID-19, COVID-19 in hospitalized adults and pediatric children, pre-exposure prophylaxis (PrEP), or for post-exposure prophylaxis (PEP) is determined by the [Washington State Department of Health](#) (DOH). This policy describes the requirements that facilities, providers, and pharmacies must abide by to receive and use the COVID-19 therapies listed in this policy for the treatment of COVID-19. For general information about COVID-19, see HCA's [Information about novel coronavirus \(COVID-19\) webpage](#).

During the PHE, a pharmacist may prescribe, administer, and bill for COVID-19 therapies for the treatment of mild to moderate COVID-19 when there is a standing order or a collaborative practice agreement in place. Pharmacies may bill for COVID-19 therapies for the treatment of mild to moderate COVID-19 or when used for PrEP or PEP and the pharmacist administers the product in the pharmacy.

The administration of these products must be billed as a HIPAA 837 transaction using the pharmacy billing taxonomy of 193200000X.

**Providers should not bill for products received free through the USG-purchased inventory.** Providers should only bill Medicaid for commercially purchased products.

This policy applies to HCA fee-for-service and contracted managed care organizations

### Billing information for Professional and Facility Claims:

#### Reimbursement information and billing guidance

The COVID-19 therapies and their specific administration codes listed, are covered by Apple Health (Medicaid) for the treatment of COVID-19.

When COVID-19 therapy doses are provided by the government without charge, providers should only bill for the administration. Health care providers should not include the COVID-19 therapy codes on the claim when the product is provided for free.

Please see the [COVID-19 fee schedule](#) for rates and effective dates.

#### Outpatient hospital facility

CMS established modifier "PN" (Non-expected service provided at an off-campus, outpatient, provider-based department of a hospital) to identify and pay non-expected items and services billed on an institutional claim. For COVID-19 therapy treatment, non-expected off-campus provider-based

departments of a hospital are required to report this modifier on each claim line with a HCPCS for non-excepted items and services.

## Medical necessity

Drug	Medical Necessity
Tocilizumab	Tocilizumab may be considered medically necessary when prescribed for the treatment of coronavirus disease 2019 in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), in accordance with the Emergency Use Authorization (EUA), National Institutes of Health (NIH) COVID-19 Treatment Guidelines, and DOH requirements.
Remdesivir (Veklury)	Remdesivir may be considered medically necessary when prescribed for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) with positive results of direct severe acute respiratory syndrome 2 (SARS-CoV-2) viral testing, in accordance with the Emergency Use Authorization (EUA), National Institutes of Health (NIH) COVID-19 Treatment Guidelines, and DOH Requirements, who are: <ul style="list-style-type: none"> <li>• Hospitalized; <b>OR</b></li> <li>• Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.</li> </ul>
Nirmatrelvir+ritonavir (Paxlovid)	Nirmatrelvir+ritonavir may be considered medically necessary when prescribed for the treatment of mild to moderate COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kg) with positive results of direct SARS-CoV-2, and who are at high risk for progression to severe COVID-19, including hospitalization or death in accordance with the Emergency Use Authorization (EUA), National Institutes of Health (NIH) COVID-19 Treatment Guidelines, and DOH requirements.
Molnupiravir	Molnupiravir may be considered medically necessary when prescribed for the treatment of mild to moderate COVID-19 in adults with positive results of direct SARS-CoV-2, and who are at high risk for progression to severe COVID-19, including hospitalization or death in accordance with the Emergency Use Authorization (EUA), National Institutes of Health (NIH) COVID-19 Treatment Guidelines, and DOH requirements.
Tixagevimab+cilgavimab (Evusheld)	Tixagevimab+cilgavimab may be considered medically necessary when prescribed for pre-exposure prophylaxis of COVID-19 in adults and pediatric patients (12 years of age or older weighing at least 40 kg), in accordance with the Emergency Use Authorization (EUA), National Institutes of Health (NIH) COVID-19 Treatment Guidelines, and DOH requirements, who: <ul style="list-style-type: none"> <li>• Are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2</li> </ul> <b>AND</b>

	<ul style="list-style-type: none"> <li>• Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments <b>and</b> may not mount an adequate immune response to COVID-19 vaccination <b>OR</b></li> <li>• For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g. severe allergic reaction) to a COVID-19 vaccine and/or COVID-19 vaccine component(s).</li> </ul>
Bebtelovimab	<p>Bebtelovimab may be considered medically necessary when prescribed for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg), in accordance with the Emergency Use Authorization (EUA), National Institutes of Health (NIH) COVID-19 Treatment Guidelines, and DOH requirements, who:</p> <ul style="list-style-type: none"> <li>• Have positive results of direct SARS-CoV-2 viral testing; AND</li> <li>• Are at high risk for progression to severe COVID-19, including hospitalization or death; AND</li> <li>• Alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.</li> </ul>

### Clinical policy:

Clinical Criteria	
<p><b>Mild to moderate COVID-19 at high risk for progressing to severe COVID-19 or hospitalization</b></p> <p>Bebtevolimab Molnupiravir Nirmatrelvir+ritonavir Remdesivir</p>	<p>Healthcare providers must document in the patient’s medical record that the patient/caregiver has been:</p> <ol style="list-style-type: none"> <li>1. For products authorized under EUA, communicated information consistent with and provided the <a href="#">“Molnupiravir Fact Sheet for Patients, Parents and Caregivers,”</a> <a href="#">“Nirmatrelvir+ritonavir Fact Sheet for Patients, Parents, and Caregivers,”</a> or <a href="#">“Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization (EUA) of Bebtelovimab for Coronavirus Disease 2019 (COVID-19)”</a> prior to administering the medication; <b>AND</b></li> <li>2. Informed of alternatives prior to receiving these medications; <b>AND</b></li> <li>3. For products authorized under EUA, informed that these medications are unapproved drugs that are authorized for use under Emergency Use Authorization; <b>AND</b></li> <li>4. For molnupiravir and bebtelovimab, alternative COVID-19 treatment options authorized by the FDA are not accessible or clinically appropriate.</li> <li>5. Patient will be monitored for at least 1 hour after infusion or injection is complete.</li> </ol>

<p><b>COVID-19 in hospitalized adults and pediatric children</b> Tocilizumab Remdesivir</p>	<p>Healthcare providers must document in the patient’s medical record that the patient/caregiver has been:</p> <ol style="list-style-type: none"> <li>1. For products authorized under EUA, communicated information consistent with and provided the <a href="#">“Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) for Actemra (tocilizumab)”</a> prior to administering the medication. If providing this information will delay the administration of tocilizumab to a degree that would endanger the life of a patient, the information must be provided to the patient/caregiver as soon as feasible after tocilizumab administration; <b>AND</b></li> <li>2. Informed of alternatives prior to receiving these medications; <b>AND</b></li> <li>3. Informed that these medications are unapproved drugs that are authorized for use under Emergency Use Authorization</li> </ol>
<p><b>Pre-exposure Prophylaxis (PrEP)</b> Tixagevimab+Cilgavimab</p>	<p>Healthcare providers must document in the patient’s medical record that the patient/caregiver has been:</p> <ol style="list-style-type: none"> <li>1. Communicated information consistent with and provided the <a href="#">“Tixagevimab+Cilgavimab Fact Sheet for Patients, Parents, and Caregivers”</a> prior to administering the medication; <b>AND</b></li> <li>2. Informed of alternatives prior to receiving these medications; <b>AND</b></li> <li>3. Informed that these medications are unapproved drugs that are authorized for use under Emergency Use Authorization (EUA); <b>AND</b></li> <li>4. Patient will be monitored for at least 1 hour after injections.</li> </ol>

## Dosage and quantity limits

Drug	Dose and Quantity Limits
Tocilizumab	<ul style="list-style-type: none"> <li>• Patients less than 30 kg: 12 mg/kg, max 2 infusions</li> <li>• Patients at or above 30 kg: 8 mg/kg, max 800 mg per infusion, max 2 infusions</li> </ul>
Remdesivir	<p>Loading dose:</p> <ul style="list-style-type: none"> <li>• 3 kg to less than 40 kg: 5 mg/kg</li> <li>• 40 kg and higher: 200 mg</li> </ul> <p>Maintenance:</p> <ul style="list-style-type: none"> <li>• 3 kg to less than 40 kg: 2.5 mg/kg</li> <li>• 40 kg and higher: 100 mg</li> </ul>
Nirmatrelvir+ritonavir	<ul style="list-style-type: none"> <li>• 300 mg nirmatrelvir + 100 mg ritonavir twice daily for 5 days</li> </ul>
Molnupiravir	<ul style="list-style-type: none"> <li>• 800 mg every 12 hours for 5 days</li> </ul>
Tixagevimab+cilgavimab	<ul style="list-style-type: none"> <li>• 300 mg tixagevimab + 300 mg cilgavimab</li> </ul>
Bebtelovimab	<ul style="list-style-type: none"> <li>• 175 mg bebtelovimab</li> </ul>

**Coding:**

HCPCS Code	Description
Q0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 300 mg
Q0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg
Q0222	Injection, bebtelovimab, 175 mg
M0220	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring
M0221	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring
M0223	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency
Q0249	Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, 1 mg
M0249	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, first dose

M0250	Intravenous infusion, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) only, includes infusion and post administration monitoring, second dose
J0248	Injection, remdesivir, 1 mg when administered in an outpatient setting

## Providers

- In accordance with the DOH requirements, healthcare providers must communicate to patients or parents/caregivers, as age appropriate, information consistent with the [“Tocilizumab Fact Sheet for Patients, Parents, and Caregivers,”](#) [“Nirmatrelvir+ritonavir Fact Sheet for Patients, Parents, and Caregivers,”](#) [“Molnupiravir Fact Sheet for Patients, Parents, and Caregivers,”](#) [“Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization \(EUA\) of Bebtelovimab for Coronavirus Disease 2019 \(COVID-19\),”](#) or [“Tixagevimab+cilgavimab Fact Sheet for Patients, Parents, and Caregivers”](#) (and provide a copy of the Fact Sheet) prior to the patient receiving the medication (If delay in tocilizumab or remdesivir administration would endanger the life of the patient, the tocilizumab fact sheet must be provided to the patient/caregiver as soon as feasible after infusion), including:
  - FDA has authorized the emergency use of Paxlovid, molnupiravir, or bebtelovimab for the treatment of mild to moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kg, and who are at high risk for progression to severe COVID-19, including hospitalization or death, in accordance with the Emergency Use Authorization (EUA).
  - FDA has authorized the emergency use of tocilizumab for coronavirus disease 2019 in hospitalized adults and pediatric patients (2 years of age or older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO), in accordance with the Emergency Use Authorization (EUA).
  - Remdesivir is FDA approved for adults and pediatric patients (28 days of age and older weighing at least 3 kg) with positive results of direct severe acute respiratory syndrome 2 (SARS-CoV-2) viral testing who are:
    - Hospitalized; **OR**
    - Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.
  - FDA has authorized the emergency use of Evusheld for pre-exposure prophylaxis of COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg), in accordance with the Emergency Use Authorization (EUA), and:
    - Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 **AND**
      - Who have moderate to severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and may not mount an adequate immune response to COVID-19 vaccination **OR**
      - For whom vaccination with any available COVID-19 vaccine, according to the approved or authorized schedule, is not recommended due to a history of severe adverse reaction (e.g. severe allergic reaction) to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s).

- The patient or parent/caregiver has the option to accept or refuse tocilizumab, Paxlovid, molnupiravir, bebtelovimab or Evusheld.
  - The significant known and potential risks and benefits of tocilizumab, Paxlovid, molnupiravir, bebtelovimab, and Evusheld and the extent to which such potential risks and benefits are unknown.
  - Information on available alternative treatments and the risks and benefits of those alternatives, including clinical trials.
  - Patients treated with remdesivir, Paxlovid, molnupiravir or bebtelovimab should continue to self-isolate and use infection control measures (e.g., wear mask, isolate, social distance, avoid sharing personal items, clean and disinfect “high touch” surfaces, and frequent handwashing) according to CDC guidelines.
2. • The prescribing health care provider and/or provider’s designee are/is responsible for mandatory reporting of all medication errors and serious adverse events potentially related to tocilizumab treatment within 7 calendar days from the onset of the event. These reports are to be submitted to FDA MedWatch. See “[Fact Sheet for Healthcare Providers Emergency Use Authorization \(EUA\) for Tocilizumab](#),” “[Fact Sheet for Healthcare Providers Emergency Use Authorization \(EUA\) for Paxlovid](#),” “[Fact Sheet for Healthcare Providers Emergency Use Authorization \(EUA\) for Molnupiravir](#),” “[Fact Sheet for Health Care Providers: Emergency Use Authorization for Bebtelovimab](#),” or “[Fact Sheet for Healthcare Providers Emergency Use Authorization \(EUA\) for Evusheld \(tixagevimab co-packaged with cilgavimab\)](#)” for respective reporting requirements.
- Pre-exposure prophylaxis with Evusheld is **NOT** a substitute for vaccination against COVID-19 in individuals for whom COVID-19 vaccination is recommended.
  - ACTEMA subcutaneous injection is **NOT** authorized for the treatment of COVID-19 patients.
  - Actemra for COVID-19 is **NOT** authorized to be used outside the hospital (i.e. for non-hospitalized patients).

## References

1. Apple Health (Medicaid) Monoclonal Antibody Treatment for COVID-19 clinical policy. Washington State Health Care Authority. <https://www.hca.wa.gov/assets/billers-and-providers/apple-health-mono-clonal-antibody-treatment-COVID-19-clinical-policy.pdf>
2. Information About Novel Coronavirus. Washington State Health Care Authority. <https://www.hca.wa.gov/information-about-novel-coronavirus-covid-19>.
3. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) for Actemra (tocilizumab). <https://www.fda.gov/media/150321/download>. Accessed 1/28/2022.
4. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) for Molnupiravir. <https://www.fda.gov/media/155054/download>. Accessed 1/28/2022.
5. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) for Paxlovid. <https://www.fda.gov/media/155050/download>. Accessed 1/28/2022.
6. Fact Sheet for Health Care Providers: Emergency Use Authorization (EUA) for Evusheld. <https://www.fda.gov/media/154701/download>. Accessed 3/23/2022
7. Fact Sheet for Health Care Providers: Emergency Use Authorization for Bebtelovimab. <https://www.fda.gov/media/156152/download>. Accessed 2/24/2022.
8. Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization (EUA) of Tocilizumab for the Treatment of Coronavirus Disease 2019 (COVID-19). <https://www.fda.gov/media/150320/download>. Accessed 1/4/2022.
9. Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization (EUA) of Molnupiravir for the treatment of Coronavirus Disease 2019 (COVID-19). <https://www.fda.gov/media/155055/download>. Accessed 1/4/2022.

10. Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization (EUA) of Paxlovid for Coronavirus Disease 2019 (COVID-19). <https://www.fda.gov/media/155051/download>. Accessed 1/28/2022.
11. Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization (EUA) of EVUSHELD for Coronavirus Disease 2019 (COVID-19). <https://www.fda.gov/media/154702/download>. Accessed 3/23/2022.
12. Fact Sheet for Patients, Parents, and Caregivers Emergency Use Authorization (EUA) of Bebtelimumab for Coronavirus Disease 2019 (COVID-19). <https://www.fda.gov/media/156153/download>. Accessed 2/24/2022.
13. Frequently Asked Questions on the Emergency Use Authorization for Actemra (Tocilizumab) for Treatment of COVID-19. <https://www.fda.gov/media/150345/download>. Accessed 1/28/2022.
14. Frequently Asked Questions on the Emergency Use Authorization for Paxlovid for Treatment of COVID-19. <https://www.fda.gov/media/155052/download>. Accessed 1/28/2022.
15. Frequently Asked Questions on the Emergency Use Authorization for Molnupiravir for Treatment of COVID-19. <https://www.fda.gov/media/155056/download>. Accessed 1/5/2022.
16. Frequently Asked Questions on the Emergency Use Authorization for Evusheld (tixagevimab co-packaged with cilgavimab) for Pre-Exposure Prophylaxis (PrEP) of COVID-19. <https://www.fda.gov/media/154703/download>. Accessed 3/23/2022.
17. Frequently Asked Questions on the Emergency Use Authorization of Bebtelimumab for the Treatment of COVID-19. <https://www.fda.gov/media/156154/download>. Accessed 2/24/2022.
18. Interim Guidance on Duration of Isolation and Precautions for Adults with COVID-19. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html>.
19. REGEN-COV: Subcutaneous Injection Instructions for Healthcare Providers. <https://www.phe.gov/emergency/events/COVID19/therapeutics/Documents/REGEN-COV-SubQ-FactSheet-July2021-508.pdf>. Accessed 1/28/2022.
20. The COVID-19 Treatment Guidelines Panel’s Statement on Therapies for High-Risk, Nonhospitalized Patients with Mild to Moderate COVID-19. <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/>. Accessed 1/28/2022.
21. The COVID-19 Treatment Guidelines Panel’s Statement on the Use of Anti-SARS-CoV-2 Monoclonal Antibodies or Remdesivir for the Treatment of COVID-19 in Nonhospitalized Patients When Omicron Is the Predominant Circulating Variant. <https://files.covid19treatmentguidelines.nih.gov/guidelines/archive/statement-on-anti-sars-cov-2--12-23-2021.pdf>. Accessed 1/12/2022.
22. Gottlieb R, Vaca C, Paredes R, et al. Early Remdesivir to Prevent Progression to Severe COVID-19 in Outpatients. N Engl J Med 2022; 386:305-315.
23. Veklury Prescribing Information. Gilead Sciences, Foster City, CA, 2022. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2022/214787s011lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/214787s011lbl.pdf).

## History

Date	Action and Summary of Changes
9/14/2022	Removed the following statement: <ul style="list-style-type: none"> <li>• As of 1/1/21 claims billed with the PN modifier are paid at 46% EAPG rates. Providers are subject to post pay review. If it found that modifier PN should have been used at the time of billing, recoupment of payment may occur.</li> </ul>
8/19/2022	Updating policy to include statement: <ul style="list-style-type: none"> <li>• Providers should not bill for products received free through the USG-purchased inventory. Providers should only bill Medicaid for commercially purchased products.</li> </ul>



<b>5/10/2022</b>	Updating policy to include: <ul style="list-style-type: none"> <li>• FDA label update for remdesivir</li> </ul>
<b>4/12/2022</b>	Updating policy to include: Updated clinical policy and billing codes to reflect products (casirivimab+imdevimab, bamlanivimab+etesevimab and sotrovimab) that are no longer authorized
<b>3/23/2022</b>	Updating policy to include: <ul style="list-style-type: none"> <li>• Updated dosage and quantity limits for tixagevimab+cilgavimab</li> </ul> Updated billing codes
<b>2/24/2022</b>	Updating policy to include: Updated FDA label for bebtelovimab
<b>1/28/2022</b>	Updating policy to include: <ul style="list-style-type: none"> <li>• Updated FDA label for remdesivir</li> </ul> Updated EUA for remdesivir
<b>1/18/2022</b>	Updating policy to include: <ul style="list-style-type: none"> <li>• Use of Paxlovid and molnupiravir for mild to moderate COVID-19.</li> <li>• Use of Evusheld for pre-exposure prophylaxis.</li> <li>• Use of remdesivir for hospitalized patients with suspected or laboratory confirmed COVID-19.</li> <li>• Use of remdesivir for non-hospitalized patients from recent NIH treatment guidelines.</li> </ul> Updated: <ul style="list-style-type: none"> <li>• Hyperlinks, provider requirements, and HCPCS codes.</li> <li>• Bamlanivimab+etesevimab dosing.</li> </ul> Title of policy from “Monoclonal antibody for treatment of COVID-19” to “Therapies for COVID-19”.
<b>9/22/2021</b>	Updating policy to include use of casirivimab + imdevimab and bamlanivimab + etesevimab for post-exposure prophylaxis. Updating policy to include tocilizumab. Updated hyperlinks, provider requirements, and HCPCS codes. Added resource information for subcutaneous administration of casirivimab + imdevimab. Added information for providers for limitations of authorized use.
<b>7/1/2021</b>	Updating policy to include sotrovimab
<b>4/20/2021</b>	Removed bamlanivimab as emergency use authorization was revoked.
<b>3/2/2021</b>	Updating policy to include bamlanivimab + etesevimab
<b>12/18/2020</b>	New policy